Potential of DMXAA combination therapy for solid tumors

Expert Review of Anticancer Therapy

Volumn 2, Issue 5, 2002, Pages 593-603

  Baguley, Bruce C ^a   Wilson, William R ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Antivascular; Cytotoxic; DMXAA; Gene therapy; Immunomodulation; Radiation; Tumor necrosis factor

Indexed keywords

1,2,3 BENZOTRIAZINE DERIVATIVE; 1,4 BIS[[2 (DIMETHYLAMINO N OXIDE)ETHYL]AMINO] 5,8 DIHYDROXYANTHRAQUINONE; 5 HYDROXYINDOLEACETIC ACID; 5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; ANGIOGENESIS INHIBITOR; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; CARBOPLATIN; CISPLATIN; COLCHICINE; COMBRETASTATIN A4; CYCLOPHOSPHAMIDE; CYTOKINE; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; ENDOTOXIN; ETOPOSIDE; FLUOROURACIL; MELPHALAN; MITOFLAXONE; PACLITAXEL; THALIDOMIDE; TIRAPAZAMINE; TUMOR NECROSIS FACTOR; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE; XANTHONE 4 ACETIC ACID; 5,6 DIMETHYLXANTHENONEACETIC ACID; 5,6-DIMETHYLXANTHENONEACETIC ACID; XANTHENE DERIVATIVE; XANTHONE DERIVATIVE;

AREA UNDER THE CURVE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER TISSUE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG CLASSIFICATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TOLERABILITY; EXPERIMENTAL NEOPLASM; GENE THERAPY; HUMAN; HYPERTHERMIA; NONHUMAN; RADIOIMMUNOTHERAPY; REVIEW; SIDE EFFECT; SOLID TUMOR; TUMOR VASCULARIZATION; ANIMAL; GENETICS; MULTIMODALITY CANCER THERAPY; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS; COMBINED MODALITY THERAPY; GENE THERAPY; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; XANTHENES; XANTHONES;

EID: 0036796195     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.2.5.593     Document Type: Review

References (84)

1. Denekamp J. Vascular attack as a therapeutic strategy for cancer Cancer Metastasis Rev. 9(3), 267-282 (1990).
2. Auerbach W, Auerbach P, Angiogenesis inhibition: a review. Pharmacol. Ther. 63, 265-311 (1994).
3. Rewcastle GW, Atwell GJ, Zhuang I, Baguley BC, Denny WA. Potential antitumor agents. 61. Structure-activity relationships for in vivo colon 38 activity among disubstituted 9-oxo-9H-xanthene-4-acetic acids. J. Med. Chem. 34(1), 217-222 (1991).
4. Rustin G, Galbraith S, Taylor N et al. Impact on tumour perfusion measured by dynamic magnetic resonance imaging (MRI), in the Phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Ann. Oncol. 9, 126 (1998).
5. Jameson MB, Thompson PI, Baguley BC et al. Phase I pharmacokinetic and pharmacodynamic study of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent. Proc. Am. Soc. Clin. Oncol. 19, 182a (2000).
6. Starnes CO. Coley's toxins in perspective. Nature 357, 11-12 (1992).
7. Hobohm U. Fever and cancer in perspective. Cancer Immunol. Immunother. 50, 391-396 (2001).
8. Old LJ. Tumor necrosis factor (TNF). Science 230, 630-632 (1985).
9. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl Acad. Sci. USA 25, 3666-3670 (1975).
10. Lienard D, Ewalenko P, Delmotte P, Renard JJ, Lejeune F. High-dose recombinant tumor necrosis factor-α in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J. Clin. Oncol. 10, 52-60 (1992).
11. MacPherson GG, Niorth RJ. Endotoxin-mediated necrosis and regression of established tumours in die mouse. A corrlative study of quantitative changes in blood flow and morphology. Cancer Immunol. Immunother 21(3), 209-216 (1986).
12. Pimm MV, Gribben SJ, Morris TM. Influence of recombinant tumour necrosis factor-α on blood flow and antibody localisation in human tumour xenografts in nude mice. J. Cancer Res. Clin. Oncol. 117(6), 543-548 (1991).
13. Smith GP, Calveley SB, Smith MJ, Baguley BC. Flavone acetic acid (NSC 347512) induces haemorrhagic necrosis of mouse colon 26 and 38 tumours. Eur. J. Cancer Clin. Oncol. 23, 1209-1212 (1987).
14. Baguley BC, Calveley SB, Crowe KK, Fray LM, O'Rourke SA, Smith GP. Comparison of the effects of flavone acetic acid, fostriecin, homoharringtonine and tumour necrosis factor-a on Colon 38 tumors in mice. Eur. J. Cancer Clin. Oncol. 25, 263-269 (1989).
15. Plowman J, Narayanan VL, Dykes D et al. Flavone acetic acid. a novel agent with preclinical antitumor activity against colon adenocarcinoma 38 in mice. Cancer Treat. Rep. 70, 631-638 (1986).
16. Evelhoch JL, Bissery M-C, Chabot GG et al. Flavone acetic add (NSC 347512)-induced modulation of murine tumor physiology monitored by in vivo nuclear magnetic resonance spectroscopy. Cancer Res. 48, 4749-4755 (1988).
17. Zwi LJ, Baguley BC, Gavin JB, Wilson WR. Blood flow failure as a major determinant in the antitumor action of flavone acetic acid (NSC 347512). J. Natl Cancer Inst. 81, 1005-1013 (1989).
18. Mace KF, Hornung RL, Wiltrout RH, Young HA. Correlation between in vivo induction of cytokine gene expression by flavone acetic acid and strict close-denpency and therapeutic efficacy against murine renal cancer. Cancer Res. 50(6), 1742-1747 (1990).
19. Kerr DJ, Kaye SB. Flavone acetic acid-preclinical and clinical activity. Eur. J. Cancer Clin. Oncol. 25, 1271-1272 (1989).
20. Zwi LJ, Baguley BC, Gavin JB, Wilson WR. Correlation between immune and vascular activities of xanthenone acetic acid antitumor agents. Oncol. Res. 6, 79-85 (1994).
21. Atwell GJ, Rewcastle GW, Baguley BC, Denny WA. Potential antitumor agents. 60. Relationships between structure and in vivo colon 38 activity for 5-substituted 9-oxoxanthene-4-acetic acids. J. Med. Chem. 33, 1375-1379 (1990).
22. Lash CJ, Li AE, Rutland M, Baguley BC, Zwi LJ, Wilson WR. Enhancement of the antitumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs. Br. J. Cancer 78, 439-445 (1998).
23. Pedley RB, Sharma SK, Boxer GM et al. Enhancement of antibody-directed enzyme prodrug therapy in colorectal xenografts by an antivascular agent. Cancer Res. 59(16), 3998-4003 (1999).
24. Siim BG, Laux WT, Rutland MD, Palmer BN, Wilson WR. Scintigraphic imaging of the hypoxia marker (99m)Techtnetium-labeled 2,2′-1,4-diaminobutane)bis(2-methyl-3-butanone) dioxime (Tc-99m-labeled HL-91; Prognox): noninvasive detection of tumor response to the antivascular agent 5,6-dimethylxanthenone-4-acetic acid. Cancer Res. 60(16), 4582-4588 (2000).
25. Philpott M, Baguley BC, Ching L-M. Induction of tumour necrosis factor-α by single and repeated doses of the antitumor agent 5,6-dimethylxanthenone4-acetic acid. Cancer Chemother. Pharmacol. 36, 143-148 (1995).
26. Ching L-M, Xu Z-F, Gummer BH, Palmer BD, Joseph WR, Baguley BC. Effect of thalidomide on tumour necrosis factor production and antitumour activity induced by 5,6-dimethylxanthenone-4-acetic acid. Br. J. Cancer 72, 339-343 (1995).
27. Cao Z, Joseph WR, Browne WL et al. Thalidomide increases both intra-tumoural tumour necrosis factors production and antitumour activity in response to 5,6-dimethylxanthenone-4-acetic acid. Br. J. Cancer 80(5-6), 716-723 (1999).
28. Ching LM, Goldsmith D, Joseph WR, Korner H, Sedgwick JD, Baguley BC. Induction of intratumoral tumor necrosis factor (INF) synthesis and hemorrhagic necrosis by 5,6-dimethylxantenone-4-acetic acid (DMXAA) in TNF knockout mice. Cancer Res. 59(14), 3304-3307 (1999).
29. Zhao L, Baguley BC, Kestell P, Ching L-M. The antitumour activity of 5,6-dimethylxanthenone-4-acedc acid (DMXAA) in TNF receptors-1 knockout mice. Br. J. Cancer (2002) (In Press).
30. Ching LM, Joseph WF, Crosier KE, Baguley BC. Induction of tumor necrosis factors messenger RNA in human and murine cells by the flavone acetic acid analogue 5,6-dimedithylxanthenone-4-acetic acid (NSC 640488). Cancer Res. 54, 870 872 (1994).
31. Baguley BC, Holdaway KM, Thomsen LL, Zhuang L, Zwi LJ. Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine - evidence for a vascular mechanism. Eur. J. Cancer 27(4), 482-487 (1991).
32. Ludford RJ. Colchicine in the experimental chemotherapy of cancer. J. Natl Cancer Inst. 6, 411-441 (1945).
33. Hill SA, Lonergan SJ, Denekamp J, Chaplin DJ. Vinca alkaloids - antivascular effects in a murine tumour. Eur. J. Cancer 29A, 1320-1324 (1993).
34. Hill SA, Lonergan SJ, Denekamp J, Chaplin DJ. The effect of Vinca alkaloids on tumour blood flow. Adv. Exp. Med. Biol. 345, 417-422 (1994).
35. Baguley BC, Zhuang L, Kestell P. Increased Plasma serotonin following treatment with flavone-8-acetic acid, 5,6-dimethlylxanthenone-4-acetic acid, vinblastine and colchicine - relation to vascular effects. Oncol. Res. 9(2), 55-60 (1997).
36. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by Taxol. Nature 277, 665-667 (1979).
37. Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR, Chaplin DJ. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res. 57(10), 1829-1834 (1997).
38. Stratford M, Folkes L, Galbraith S et al. Phase I pharmacokinetic and toxicity study of weekly iv. combretastatin A4 phosphate (CA4P). Clin. Cancer Res. 6, S280 (2000).
39. Ching L-M, Cao Z, Kieda C, Swain S, Jameson MB, Baguley BC. Induction of endothelial cell apoptosis by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid. Br. Cancer 86, 1937-1942 (2002).
40. Kestell P, Zhao L, Jameson M, Stratford MRL, Folkes LY, Baguley BC. Measurement of plasma 5-hydroxyindoleacetic acid as a possible clinical surrogate marker for the action of antivascular agents. Clin. Chim. Acta 314, 159-166 (2001).
41. Yi ES, Ulich TR. Endotoxin, interieukin-1 and tumor necrosis factor cause neutrophil dependent microvascular leakage in postcapillary venules. Am. J. Pathol. 140(3), 659-663 (1992).
42. Thomsen LL, Ching LM Zhuang I, Gavin JB, Baguley BC. Tumor-dependent increased plasma nitrate concentrations as an indication of the antitumor effect of flavone-8-acetic acid and analogues in mice. Cancer Res. 510), 77-81 (1991).
43. Philpott M, Ching LM, Baguley BC. The antitumour agent 5,6-dimethylxanthenone4-aceric acid acts in vitro on human mononuclear cells as a co-stimulator to other inducers of tumour necrosis factor. Eur. J. Cancer 37, 1930-1937 (2001).
44. Ching LM, Joseph WP, Baguley BC. Antitumour responses to flavone-8-acetic acid and 5,6-dimethylxandienone-4-acetic acid in immune deficient mice. Br. J Cancer 66(1), 128-130 (1992).
45. Yin MJ, Yamamoto Y, Gaynor RB. The anti-inflammitory agents aspirin and salicylate inhibit the activity of IκB kinase-P. Nature 396(6706), 77-80 (1998).
46. Pedley RB, Boden JA. Boden R et al. Ablation of colorectal xenografts with combined radioinimunotherapy and tumor blood flow-modifying agents. Cancer Res. 56(14), 3293-3300 (1996).
47. Chaplin DJ, Pettit GR. Parkins CS, Hill SA. Antivascular approaches to solid tumour therapy - evaluation of tubulin binding agents. Br. J. Cancer 74, S86-S88 (1996).
48. Brown JM, Giaccia AJ. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res. 58(7), 1408-1416 (1998).
49. Tannock IF. Tumor physiology and drug resistance. Lancet 351, 9-16 (1998).
50. Pruijn FB, van Daalen M, Holford NHG, Wilson WR. Mechanisms of enhancement of the antitumour activity of melphalan by the tumour blood flow inhibitor 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemother Pharmacol. 39, 541-546 (1997).
51. Horsman MR, Murata R, Overgaard J. Improving local tumor control by combining vascular targeting drugs, mild hyperthermia and radiation. Acta Oncol. 40(4), 497-503 (2001).
52. Schreck R, Albermann K, Baeuerle PA. Nuclear factor kappa B - an oxidative stress-responsive transcription factor of eukaryotic cells (a review). Free. Radic. Res. Commun. 17, 221-237 (1992).
53. Wilson WR, Li AE, Cowan DSM, Siim BG. Enhancement of tumor radiation response by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Int. J. Radiat. Oncol. Biol. Phys. 42(4), 905-908 (1998).
54. Murata R, Siemann DW, Overgaard J, Horsman MR. Improved tumor response by combining radiation and the vascular-damaging drug 5,6-dimethylxanthenone-4-acetic acid. Radiat. Res. 156, 503-509 (2001).
55. Cliffe S, Taylor ML, Rutland M, Baguley BC, Hill RP, Wilson WR. Combining bioreductive drugs (SR 4233 or SN 23862) with the vasoactive agents flavone acetic acid or 5,6-dimethylxanthenone acetic acid. Int. J. Radiat. Oncol. Biol. Phys. 29, 373 377 (1994).
56. Wilson WR, Pruijn FB. Hypoxia-activated prodrugs as antitumour agents: strategies for maximising tumour cell killing. Clin. Exp. Pharmacol. Physiol. 22, 881-885 (1995).
57. Wilson WR, Denny WA, Pullen SM et al. Tertiary amine N-oxides as bioreductive drugs: DACA N-oxide, nitracrine N-oxide and AQ4N. Br. J. Cancer 74, S43-S47 (1996).
58. Vincent PW, Roberts BJ, Elliott WL, Leopold WR. Chemotherapy with DMXAA (5,6-dimethylxanthenone-4-acetic acid) in combination with CI-1010 (1H-in,imidazole-1-ethanol,alpha-[[(2-bromoethyl)amino]methyl] -2-nitro-, monohydrobromide (R isomer)) against advanced stage murine colon carcinoma 26. Oncol. Rep. 4(1), 143-147 (1997).
59. Wilson WR, Vanzijl P, Denny WA. Bisbioreductive agents as hypoxia-selective cytotoxins - nitracrine N-oxide. Int. J. Radiat. Oncol. Biol. Phys. 22, 693-696 (1992).
60. Wilson WR, Siim BG, Denny WA et al. 5-nitro-4-(N,N-dimethylaminopropylamino)quinoline (5-nitraquine), a new DNA-affinic hypoxic cell radiosensitizer and bioreductive agent comparison with nitracrine. Radiat. Res. 131(3), 257-265 (1992).
61. Siim BG, Denny WA, Wilson WR. Does DNA targeting affect the cytotoxicity and cell uptake of basic nitroquinoline bioreductive drugs? Int. J. Radiat. Oncol. Biol. Phys. 29, 311-315 (1994).
62. Baguley BC. Novel strategies for overcoming multi-drug resistance in cancer. BioDrugs 16, 97-103 (2002).
63. Wang CY, Mayo MW, Baldwin AS. TNF and cancer therapy-induced apoptosis - potentiation by inhibition of NFκB. Science 274(5288), 784-787 (1996).
64. Wilson WR, Baguley BC. Combination of the antivascular agent DMXAA with radiation and chemotherapy. Int. J. Radiat. Oncol. Biol. Phys. 46, 706 (2000).
65. Siemann DW, Mercer E, Lepler S, Rojiani AM. Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy. Int. J. Cancer 99 (1), 1-6 (2002).
66. Pedley RB, Begent RH, Boden JA, Boxer GM, Boden R, Keep PA. Enhancement of radioimmunotherapy by drugs modifying tumour blood flow in a colonic xenograft model. Int. J. Cancer 57(6), 830-835 (1994).
67. Murata F. Overgaard J, Horsman MR. Potentiation of the antitumour effect of hyperthermia by combining with the vascular targeting agent 5,6-dimethylxanthenone-4-acetic acid. Int. J. Hyperthermia 17(6), 508-519 (2001).
68. Van MW, Welockx B, Mahieu T et al. HSP70 protects against TNF-induced lethal inflammatory shock. Immunity 16(5), 685-695 (2002).
69. Cao Z, Baguley BC, Ching L-M. Interferon-inducible protein 10 induction and inhibition of angiogenesis in vivo by the antitumor agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Cancer Res. 61, 1517-1521 (2001).
70. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc. Natl Acad. Sci. USA 91, 4082-4085(1994).
71. Calabrese L, Resztak K. Thalidomide revisited: pharmacology and clinical applications. Exp. Opin. Investig. Drugs 7 (1998).
72. Eisen T, Boshoff C, Vaughan MM. Anti-angiogenic treatment of metatstatic melanoma, renal cell, ovarian and breast cancers with thalidomide: a Phase II study. Proc. Am. Soc. Clin. Oncol. 17, 441a (1998).
73. Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor-α production by stimulated human monocytes. J. Exp. Med 173(3), 699-703 (1991).
74. Ching LM, Browne WL, Tchernegovski R, Gregory T, Baguley BC, Palmer BD. Interaction of thalidomide, phthalimide analogues of thalidomide and pentoxifylline with the antitumour agent 5,6-dimethylxanthenone-4-acetic acid: concomitant reduction of serum tumour necrosis factor-α and enhancement of antitumour activity, Br J. Cancer 78, 336-343 (1998).
75. Keifer JA, Guttridge DC, Ashburner BP, Baldwin AS Jr. Inhibition of NF-κB activity by thalidomide through suppression of I-κB kinase activity. J. Biol. Chem 276, 22382-22387 (2001).
76. Shannon EJ, Sandoval F. Thalidomide can be either agonistic or antagonistic to LPS evoked synthesis of TNF-α by mononuclear cells. Immunopharmacol. Immunotoxicol. 18(1), 59-72 (1996).
77. Kestell P, Zhao, L, Baguley BC et al. Modulation of the pharmacokinetics of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice by thalidomide. Cancer Chemother. Pharmacol. 46, 135-141 (2000).
78. Galbraith SM, Chaplin DJ, Lee F et al. Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo. Anticancer Res. 21 (1A), 93-102 (2001).
79. Cater DB, Petrie X Watkinson DA. Effect of 5-hydroxytryptamine and cyproheptadine on tumour blood flow. Estimation by rate of cooling after microwave diathermy. Acta Radiolog. Ther. Phys. Biol. 3, 109-128 (1965).
80. Baguley BC, Cole G, Thomsen LL, Zhuang L. Serotonin involvement in the antitumour and host effects of flavone-8 acetic acid and 5,6-dimethylxanthenone-4 acetic acid. Cancer Chemother Pharmacol. 33, 77-81 (1993).
81. Zhao L, Kestell P, Philpott M, Ching L-M, Zhuang L, Baguley BC. Effects of the serotonin receptor antagonist cyproheptadine on the activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Cancer Chemother. Pharmacol. 47, 491-497 (2001).
82. Ramu A, Ramu N. Reversal of multi-drug resistance by phenothiazines and structurally related compounds. Cancer Chemother. Pharmacol. 30(3), 165-173 (1992).
83. Kanwar JR, Kanwar RK, Pandey S, Ching LM, Krissansen GW. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci. Cancer Res. 61(5), 1948-1956 (2001).
84. Simm BG, Lee AE, Shalal-Zwain S, Pruijn FB, McKeage W, Wilson WR. Marked potentiation of the aintitumor activity of chemotherapeutic drugs by antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Cancer Chemother. Pharmacol. (2002) (In Press).